Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent

The U.K. drug marketing body, the Prescription Medicines Code of Practice Authority (PMCPA), is once again taking action against Novartis' U.K. business, which has become a repeat offender in terms of "bringing discredit upon, and reducing confidence in, the pharmaceutical industry."